Study center

Our study center conducts several clinical studies in oncology, allergology/angioedema and otology at all times of the year. We need your help as a patient to successfully manage to complete those studies.

What is a clinical study and how is it conducted?

New pharmaceuticals, diagnostic procedures and medical devices need to undergo clinical studies before they can be marketed. These studies aim to evaluate their safety and effectiveness. They are conducted with volunteers (probands.

A specific study protocol lays out among other things the substance to be tested, the duration of the study, the planned study visits and examinations, the aims of the study and how to deal with adverse events.

The study protocols are approved by the ethic committee of the medical faculty of the TUM and other independent committees (e.g. Paul-Ehrlich-Institut, Bundesamt für Arzneimittel und Medizinprodukte, Bundesamt für Strahlenschutz).

All volunteers can opt out of the study at any time without further obligations.

Which types of study do exist?

Our study center primarily conducts controlled studies. In this type of study only a part of the probands receive the study medication. All other probands either receive the current standard therapy or a placebo. Probands are usually randomly assigned to one of the two groups (randomization).

Most of the studies are conducted in a double-blind fashion. In this setting neither proband nor investigator know to which study group the proband has been assigned.

Open study settings in which all probands and investigators know which substance they are receiving are much rarer.

Which types of drug trials do exist?

All drugs have to undergo certain study phases before they can be approved for market access.

Phase I

In this phase a study drug which has formerly only been tested in cell cultures and animals is tested in healthy volunteers for the first time.

Phase I studies aim to determine whether the study drug is safe, if the effects are comparable to the effects observed in animals, how the study drugs is distributed and metabolized in humans.

Phase II

In this phase drugs are used in sick volunteers for the first time. These studies serve to determine the effectivity, tolerability and the optimal dose of a drug.

Phase III

In this phase the results of the phase-II-study are being corroborated in a large patient cohort.

This usually takes place in a double blinded randomized fashion in which the new drug is compared with standard medication or placebo. Market access can be applied for after completion of these studies.

Phase IV

These studies are performed after market approval of a drug. Patients are monitored while they use a newly approved drug in routine therapy. These trials aim to monitor rare adverse events and to verify the effectivity of the medication under real life conditions.

Further studies are in preparation, if you are interested to participate in one of our studies please contact us by mail at:

We are regularly involved in pioneering new therapeutic worldwide studies. If you would like to get more information about our studies, please send an e-mail to sends e-mail).

With our studies we enable interested patients* to participate in new therapie options at an early stage. This concerns mainly pollen and mite allergies with and without asthma and chronic sinusitis with nasal polyps in adults. For example, we have contributed to studies for allergen immunotherapy for grass allergy sufferers with peptides and to new concepts for grass and birch pollen allergies (new injection therapies). We are also involved in pioneering studies for new therapies with antibodies in chronic sinusitis with nasal polyps.

Furthermore, we are conducting in-house research projects with the Center for Allergy and Environment (ZAUM(link is external)) (e.g. the PACIFIC study and the ADAPT study (ADAPT-Studie(link is external)). Here we investigate long-term biomarkers for allergen immunotherapy.

To our allergy consultation

Further information on allergy studies throughout Germany can also be found at the study portal of the Allergy Information Service(link is external).

Ongoing studies

  • ADAPT study

Within the framework of our study we would like to test diagnostic procedures in order to cooperate in the development of new diagnostic methods. No more patients can be enrolled. More information here(link is external) and at the Allergy Information Service(link is external).

  • PACIFIC study

Long-term study for biomarkers for allergy vaccination.

Upcoming studies

We are started two new studies in 2020 for the treatment of chronic rhinosinusitis with nasal polyps.

Completed studies

SYNAPSE (study on the treatment of chronic rhinosinusitis with nasal polyps with mepolizumab), TT04 (study on specific immunotherapy with a birch pollen tablet), PQ-Birch (studies on specific immunotherapy with a birch pollen injection).

If you are interested in participating in the study, or have any questions, please feel free to contact us at any time. Our contact information can be found below:

Phone +49 89 4140 6969
E-Mail(link sends e-mail)